Wednesday, May 12, 2021
ADVT 
International

Pfizer: Mid-November earliest it can seek virus vaccine OK

Darpan News Desk The Canadian Press, 16 Oct, 2020 06:39 PM
  • Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday.

Despite President Donald Trump’s repeated promises of a vaccine before Election Day, scientists have been cautioning that it’s unlikely data showing a leading shot actually works would come until November or December.

Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. But in Friday’s announcement, he made clear that effectiveness is only part of the equation.

The vaccine also must be proven safe. And to qualify for an “emergency use authorization,” any COVID-19 vaccine must track at least half the participants in large-scale studies for two months after their second dose, the time period in which side effects are likely to appear.

Bourla estimated Pfizer's 44,000-person study will reach that milestone in the third week of November.

“We are operating at the speed of science,” he wrote in a letter posted to the company’s website.

The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing.

Even if a vaccine emerges by year’s end, only limited doses will be available right away. The U.S. government is deciding who would be first in line, almost certainly health care workers, and estimates there may be enough for widespread vaccinations in the spring.

MORE International ARTICLES

Antibody drugs are no cure but seem promising for COVID-19

Antibody drugs are no cure but seem promising for COVID-19

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines mimic an infection to spur antibody production.

Antibody drugs are no cure but seem promising for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Lilly seeks emergency use of its antibody drug for COVID-19

Experts call Trump's rosy virus message misguided

Experts call Trump's rosy virus message misguided

The seven-day rolling average for new U.S. cases has climbed over the past two weeks to almost 42,000 per day. The nation also sees more than 700 COVID-19 deaths each day.

Experts call Trump's rosy virus message misguided

With Trump sick, all eyes on Wednesday's VP debate

With Trump sick, all eyes on Wednesday's VP debate

Questions persist about Donald Trump's health following his COVID-19 diagnosis, as well as the age of 77-year-old challenger Joe Biden.

With Trump sick, all eyes on Wednesday's VP debate

Magnitsky sanctions demanded in Iranian shootdown

Magnitsky sanctions demanded in Iranian shootdown

There were 176 people killed when the Iranian military shot down Ukraine International Airlines Flight PS752 on Jan. 8, shortly after it took off from Tehran.

Magnitsky sanctions demanded in Iranian shootdown

Berry scare: U.S. eyeing foreign produce imports

Berry scare: U.S. eyeing foreign produce imports

U.S. Trade Representative Robert Lighthizer served notice last week that the Trump administration fears domestic producers are being unfairly harmed by what they call a recent increase in berry imports from Canada and Mexico.

Berry scare: U.S. eyeing foreign produce imports